Schonfeld Strategic Advisors LLC Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Schonfeld Strategic Advisors LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 69.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,317 shares of the specialty pharmaceutical company's stock after selling 65,533 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Jazz Pharmaceuticals were worth $3,610,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its position in Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after buying an additional 6,289 shares during the period. Synovus Financial Corp raised its stake in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. Synovus Financial Corp now owns 19,106 shares of the specialty pharmaceutical company's stock valued at $2,129,000 after acquiring an additional 451 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after purchasing an additional 48,708 shares during the period. Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 56.7% in the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company's stock valued at $119,000 after purchasing an additional 350 shares during the period. Finally, GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 49.8% during the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company's stock worth $76,000 after purchasing an additional 206 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $9.73 during midday trading on Wednesday, reaching $101.44. 3,079,379 shares of the company traded hands, compared to its average volume of 825,049. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The firm's fifty day moving average price is $121.47 and its two-hundred day moving average price is $122.47. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of 14.29, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. During the same period in the previous year, the business earned $2.68 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis. On average, equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JAZZ. HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday. Truist Financial increased their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Morgan Stanley decreased their target price on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $182.79.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total transaction of $937,625.00. Following the transaction, the chief executive officer now directly owns 464,058 shares in the company, valued at approximately $66,940,366.50. The trade was a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is currently owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.